RT Journal Article
SR Electronic
T1 Avoiding false positive SARS-CoV-2 rapid antigen test results with point-of-care molecular testing on residual test buffer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.18.22271189
DO 10.1101/2022.02.18.22271189
A1 LeBlanc, Jason J
A1 McCracken, Gregory R.
A1 Goodall, Barbara
A1 Hatchette, Todd F
A1 Barrett, Lisa
A1 Ross, John
A1 Davidson, Ross J
A1 Patriquin, Glenn
YR 2022
UL http://medrxiv.org/content/early/2022/02/24/2022.02.18.22271189.abstract
AB Objectives Antigen-based rapid diagnostic tests (Ag-RDTs) have been widely used for the detection of SARS-CoV-2 during the Covid-19 pandemic. In settings of low disease prevalence, such as asymptomatic community testing, national guidelines recommend molecular confirmation of positive Ag-RDT results. This often requires patients to be recalled for repeat specimen recollection and subsequent testing in reference laboratories. This project assessed the use of a point-of-care molecular method for SARS-CoV-2 detection on-site at a volunteer-led asymptomatic community testing site, using the residual test buffer (RTB) from positive Ag-RDTs.Methods The Abbott COVID-19 ID NOW assay was performed on RTB from two Ag-RDTs: the Abbott Panbio COVID-19 Ag Rapid Test Device and the BTNX Rapid Response COVID-19 Antigen Rapid Test Device. All RTBs were tested using real-time RT-PCR at a reference laboratory using the ThermoFisher TaqPath COVID-19 Combo kit which was used to assign positive Ag-RDTs results as true or false positives. Analytical specificity of the ID NOW was assessed with a panel of various respiratory organisms.Results Of 419 positive Ag-RDTs from 5148 tests performed, ID NOW testing of the RTB was positive in 100% of the samples characterized as true positives by RT-PCR. No SARS-CoV-2 detections by ID NOW were observed from 10 specimens characterized as false positive Ag-RDTs, or from contrived specimens with various respiratory organisms.Conclusions The use of on-site molecular testing on RTB provides a suitable option for rapid confirmatory testing of positive Ag-RDTs, thereby obviating the need for specimen recollection for molecular testing at local reference laboratories.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work received no private or public funding, except for the Ag-RDT kits that were provided in-kind from the government of Canada. RT-PCR testing was provided in-kind by the Division of Microbiology, Department of Pathology and Laboratory Medicine, Nova Scotia Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project was deemed a quality initiative and was therefore exempt from review by the Nova Scotia Health Research Ethics Board (submission number 1027644). Specimens tested were obtained from consenting participants, and all data related were provided anonymized, de-identified, and were used solely with the intent to evaluate the performance characteristics of the different swab types for rapid antigen testing programs used in Nova Scotia.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript